Vidyya Medical News Servicesm
Vidyya, from the Sanskrit "vaidya," a practitioner who has come to understand the science of life.

Volume 1 Published - 14:00 UTC    08:00 EST    24-October-2000      
Issue 194 Next Update - 14:00 UTC 08:00 EST    25-October-2000      

Vidyya Home  Vidyya

Home Of Our Sponsor, Vidyya.  Vidyya. Home

Vidyya Archives  Vidyya Archives

Search Vidyya  Search Vidyya

Visit Our Library  Ex Libris

Subscribe To Our News Service  Subscriptions

All About Us  About Vidyya

Back To Vidyya FDA Approves New Implanted Hearing Device

Device Does Not Restore Normal Hearing

The FDA today approved a new brain stem implant designed to restore some hearing in people who experience total hearing loss when the removal of tumors damages their cranial hearing nerves.

The device, made by Cochlear Corporation of Englewood, Colo., restores the ability to detect certain sounds and speech, although it does not restore normal hearing. In clinical studies, the device worked for most, but not all, patients.

FDA expedited review of the product, the first of a kind, and approved it within six months of receipt of the manufacturer's application.

The product is an auditory brain stem implant system. It is surgically implanted into the brain and electrically stimulates the area that normally receives the electrical signal from the ear. The patient wears a pocket-size speech processor that picks up sound and changes it into electrical pulses that are transmitted to the implant.

The device was approved for use in teenagers and adults who have a rare disease called neurofibromatosis type 2 in which tumors growing on cranial nerves need to be surgically removed. Removal of tumors on the auditory nerve requires severing or cutting the nerve, which results in total loss of hearing. These patients cannot be helped by hearing aids or cochlear implants.

Approval was based on a review of clinical studies of safety and effectiveness conducted by Cochlear Corp. and on the recommendation of the Ear, Nose and Throat Devices Panel of FDA's Medical Devices Advisory Committee which met in July to evaluate the device.

In the studies, the device was implanted in some 90 people between the ages of 12 and 67 with neurofibromatosis type 2. The device was implanted during surgery to remove auditory nerve tumors. Sixty patients were evaluated for effectiveness after six months of use. (The remaining 30 had yet to reach their 6-month evaluation.)

Results varied: 82% of the 60 patients were able to detect certain familiar sounds, such as honking horns and ringing doorbells; 85% were able to hear and understand conversation with the aid of lip reading; and 12% were able to hear well enough to use the phone.

Of the 90 patients who received this implant, 18% were not able to hear any sound. This was due either to migration of the implant after surgery or misplacement of the device during surgery.

Vidyya. Home |  Ex Libris |  Vidyya  | 
Subscription Information |  About Vidyya |  Vidyya Archives | 

Editor: Susan K. Boyer, RN
© Vidyya. All rights reserved.